Ultivue develops multiplex biomarker assays that combine multiplex immunofluorescence with same-slide traditional H&E for tissue phenotyping. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples, delivering high-resolution multiplexed protein marker information on existing hardware. The company offers kit-based, highly customizable solutions and a scientific consultative approach to support academic, biopharma, and CRO customers. Ultivue positions its products to strengthen and accelerate biomarker discovery and drug development and to integrate tissue biomarkers within digital pathology workflows. The company completed a $50 million Series D financing to expand commercial efforts and increase the scope of research and development. Management and investors cited the funding as a way to remain at the forefront of innovation and help address challenges in therapeutic response rates for immunotherapy research. Ultivue develops proprietary reagents and UltiMapper™ multiplexed assay kits that enable simultaneous quantitation of multiple biomarkers in tissue with sub-cellular spatial resolution while fitting within traditional IHC workflows. Its products bridge biomarker discovery and translational use, supporting translational and clinical researchers in immuno-oncology and precision medicine research. The company also offers a menu of contract research services to connect research insights directly into pathology labs. Ultivue plans to expand its UltiMapper assay product portfolio with increased product customization and to significantly accelerate its international market presence, with an immediate focus on Asia. To support that expansion it will increase investments in sales, field application scientists, and marketing across regions. Ultivue is based in Cambridge, MA and recently completed a new financing to fund these initiatives. Ultivue develops reagent-driven solutions for high-performance in situ biological imaging centered on its InSituPlex™ multiplexed biomarker analysis technology. Its proprietary approach combines high multiplexing with high spatial resolution and is designed to integrate into existing workflows for biomarker discovery, assay validation, and companion diagnostic applications. The company plans to productize and commercialize InSituPlex, with an initial commercial focus on translational and clinical research markets and a rapid transition into regulated in vitro diagnostic markets. Ultivue is launching its first products later this year and has presented technical updates at scientific conferences. The company is led by CEO Dr. Michael Natan and was founded by Wyss Institute faculty David Walt and Peng Yin. Ultivue is based in Cambridge, MA, and recently closed a $20 million Series B to support commercialization efforts. Ultivue develops patented reagent technologies (based on DNA-PAINT and DNA-Exchange) that enable single-molecule detection and high-resolution visualization of proteins and nucleic acids for fluorescent microscopy research. Its products are designed for research use and the company says they will eventually be valuable for clinical diagnostic applications. Ultivue’s core technologies were developed at the Wyss Institute at Harvard and by collaborators, and the company holds an exclusive license from Harvard for those technologies. It also acquired rights to additional technology from the California Institute of Technology. The company was co-founded by Peng Yin and Ralf Jungmann alongside David R. Walt, whose background includes co-founding Illumina and Quanterix and academic appointments. Financially, Ultivue completed a $5.15M Series A financing to support its early-stage commercialization and development efforts.

Total raised

$97M

Funding rounds

4

Latest round

Series D

Latest activity

Apr 2021